Teva (NYSE:TEVA) is starting the week up 5.6% after signing research agreements with two leading Israeli academic institutes to boost its early-stage drug development.
A partnership with Tel Aviv University will focus on R&D in cancer and brain studies, while a collaboration with the Weizmann Institute of Science will try to identify antibodies for cancer treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.